Carbohydrate-based Antibacterial Vaccine Development

Carbohydrate-based Antibacterial Vaccine Development

The development of new technologies in glycobiology research has provided a new way to design carbohydrate vaccines. CD BioGlyco is pleased to assist our clients to develop a variety of carbohydrate-based antibacterial vaccines.

Carbohydrate-based Antibacterial Vaccine

Carbohydrate antigens on the cell surface of bacteria exist in the form of complex glycans and usually have unique structures. They are potential targets for vaccines and biomarkers. Notably, vaccines can reduce the use of antibiotics and drug resistance. For example, after the introduction of PCV conjugate vaccines into routine childhood immunization programs in some countries, the invasive bacterial diseases not only controlled and reduced the use of antibiotics in the vaccinated populations but also reduced the prevalence of antibiotic nonsusceptible strains.

Vaccination is a successful strategy to overcome the evolution of resistant strains. This has increased the development of glycoconjugate vaccines against various bacterial strains such as Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis and Salmonella typhi, which has further prompted researchers to develop vaccines against other pathogenic bacteria such as Klebsiella pneumoniae, Staphylococcus aureus, Clostridium difficile, Acinetobacter baumannii and others to fight against their antimicrobial resistance that is presently not treatable by vaccination.

Fig. 1 Synthetic protocol for the generation of the Hib capsular polysaccharide-protein conjugate for Haemophilus influenza b.Fig.1 Synthetic protocol for the generation of the Hib capsular polysaccharide-protein conjugate for Haemophilus influenza b. (Das, 2020)

Our services

CD BioGlyco has developed a professional and advanced platform to help our clients design and produce various safe and effective carbohydrate-based antibacterial vaccines, and we have established multiple strategies to improve the effectiveness of vaccines.

  • Several multivalent synthetic glycoconjugate vaccines are under development with improved immunogenicity.
  • To overcome the obstacle of autoimmunity caused by the phenomenon of similarity between bacterial antigens and host glycans, antigenic polysaccharides could be chemically modified and used as possible targets for administration to induce high affinity and long-lived antibody response in humans.
  • The antibody eliciting properties and protective effects of antigens could be enhanced by appropriately extending the chain length of antigenic carbohydrates.


  • Prevention of infection by a variety of bacteria such as Haemophilus influenzae b, Neisseria meningitidis, Streptococcus pneumoniae, Shigella, Bacillus anthracis and Brucella.
  • Reduction of antibiotic use and resistance
  • Containment and control of infectious diseases
  • Development of novel multivalent vaccines

Advantages of Us

  • Rigorous scientific attitude
  • Pioneering spirit of innovation
  • World-class experimental platform
  • Well-trained staff

As a biotechnology company with many years of experience in the field of glycobiology, CD BioGlyco focuses on carbohydrate glycan-based medicinal chemistry, helping our clients to design and synthesize novel synthetic glycoconjugate vaccines against different bacteria. Our efficient work will accelerate your research. If you are interested in our services, please contact us for more consultation.


  1. Das, R.; Mukhopadhyay, B. Carbohydrate-based anti-bacterial and anti-cancer vaccines. Carbohydrates in Drug Discovery and Development. 2020, 561-585.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.